1928zT2
/ Wellington Zhaotai Therapies
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 28, 2025
Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.
(PubMed, J Transl Med)
- P2 | "Third-generation 1928zT2 CAR-T cells are associated with high response rates, manageable safety and durable remissions in R/R B-cell malignancies with CNS involvement."
Clinical • Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TLR2
1 to 1
Of
1
Go to page
1